Sierra Leone

Ebola survivor Dr. Richard Sacra experienced eye problems, including vision loss, pain and redness, shortly after he recovered from the disease.

Credit: Chancellor JR, Padmanabhan SP, Greenough TC, Sacra R, Ellison RT III, Madoff LC, et al. Uveitis and systemic inflammatory markers in convalescent phase of Ebola virusdisease. Emerg Infect Dis. 2016 Feb

CLICK HERE - STUDY - CDC - Uveitis and Systemic Inflammatory Markers in Convalescent Phase of Ebola Virus Disease

livescience.com - by Rachael Rettner - November 25, 2015

Ebola survivor Dr. Ian Crozier wasn't the only American to experience eye problems following the disease — a new report describes eye problems in another American doctor who lived through the disease.

Dr. Richard Sacra, who works for the Christian mission organization SIM USA, contracted Ebola last year while caring for pregnant women in Liberia during the rise of the Ebola outbreak there. He was evacuated to the United States for treatment in early September 2014, and was declared Ebola-free after spending about a month in the hospital.

submitted by George Hurlburt

CLICK HERE - STUDY - Interferon-γ Inhibits Ebola Virus Infection

scicasts.com - November 19, 2015

The recent Ebola outbreak in West Africa has claimed more than 11,300 lives and starkly revealed the lack of effective options for treating or preventing the disease. Progress has been made on developing vaccines, but there is still a need for antiviral therapies to protect health care workers and local populations in the event of future outbreaks.

A new study led by University of Iowa virologist Dr. Wendy Maury, suggests that gamma interferon, which is an FDA-approved drug, may have potential as an antiviral therapy to prevent Ebola infection when given either before or after exposure to the virus.

The study, published in the journal PLOS Pathogens, found that gamma interferon, given up to 24 hours after exposure, can inhibit Ebola infection in mice and completely protect the animals from death.

PLOS PATHOGENS  by Marc-Antoine de La Vega,  Derek Stein, and GaryKopinger, University of Manitoba, Canada , Nov. 12, 2015    

Winnipeg, Manitoba, Canada The past year has marked the most devastating Ebola outbreak the world has ever witnessed, with over 28,000 cases and over 11,000 deaths. Ebola virus (EBOV) has now been around for almost 50 years. In this review, we discuss past and present outbreaks of EBOV and how those variants evolved over time. We explore and discuss selective pressures that drive the evolution of different Ebola variants, and how they may modify the efficacy of therapeutic treatments and vaccines currently being developed. Finally, given the unprecedented size and spread of the outbreak, as well as the extended period of replication in human hosts, specific attention is given to the 2014–2015 West African outbreak variant (Makona).

Read complete article.

http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1005221

submitted by George Hurlburt

(Francisco Leong / Getty News Images)

cnn.com - by Peter Guest - November 12, 2015

. . . Before the outbreak, Sierra Leone was already heavily dependent on aid money. Around 50% of public expenditure programmes were financed by donors, according to UN figures. . . .

. . . Without growth and investment, the country will struggle to create jobs for its young population -- many of whom lack stable employment -- and rebuild public services.

The government's recovery strategy, which is supported by the international community, is about "building back better," says Sudipto Mukerjee, the United Nations Development Program's country director for Sierra Leone. This is particularly relevant to the health sector, which was seriously under-developed before the crisis began, and its weakness undoubtedly contributed to the speed with which the outbreak got out of control.

"When you're talking about the health sector, you're not talking about bringing it back to where you were at the beginning of the outbreak," he says. "That's not good enough. It's also about making sure that you not only build on the investments made so far, but you invest to make it much more resilient in the future."